Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 24 Weeks, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Adult Patients With Chronic Urticaria Who Exhibit IgE Against Thyroperoxidase

NCT00481676 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00481676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00481676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 24 Weeks, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Adult Patients With Chronic Urticaria Who Exhibit IgE Against Thyroperoxidase
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
April 30, 2009
Enrollment
49 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic urticaria